Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD20”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01097057
What this trial is testing

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

Who this might be right for
Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center 20
Large-scale testing (Phase 3)Study completedNCT02303119
What this trial is testing

Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)

Who this might be right for
Follicular Lymphoma
The Lymphoma Academic Research Organisation 221
Early research (Phase 1)Not Yet RecruitingNCT07763938
What this trial is testing

CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies

Who this might be right for
Relapsed/Refractory B-cell Malignancies
The First Affiliated Hospital with Nanjing Medical University 80
Not applicableStudy completedNCT02507752
What this trial is testing

An Observational Quality of Life Study in Participants With Rheumatoid Arthritis Treated With Rituximab

Who this might be right for
Rheumatoid Arthritis
Hoffmann-La Roche 94
Not applicableActive Not RecruitingNCT06854094
What this trial is testing

Consolidation Therapy With Cladribine in Relapsing Multiple Sclerosis Patients

Who this might be right for
Multiple Sclerosis
Ente Ospedaliero Cantonale, Bellinzona 70
Very early researchNot Yet RecruitingNCT07362602
What this trial is testing

Exploratory Study on in Vivo CAR-T Therapy Targeting CD20 for the Treatment of Hematological Malignancies

Who this might be right for
Hematological Malignancies
The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army 47
Testing effectiveness (Phase 2)Study completedNCT00119392
What this trial is testing

Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
B-cell Chronic Lymphocytic LeukemiaNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt Lymphoma+14 more
Fred Hutchinson Cancer Center 42
Testing effectiveness (Phase 2)Study completedNCT02750670
What this trial is testing

Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin's
University Health Network, Toronto 30
Testing effectiveness (Phase 2)Looking for participantsNCT04110301
What this trial is testing

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Who this might be right for
Follicular Lymphoma and Marginal Zone Lymphoma
Beijing Mabworks Biotech Co., Ltd. 53
Testing effectiveness (Phase 2)Study completedNCT01682044
What this trial is testing

Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma

Who this might be right for
Contiguous Stage II Grade 1 Follicular LymphomaContiguous Stage II Grade 2 Follicular LymphomaContiguous Stage II Grade 3 Follicular Lymphoma+30 more
Roswell Park Cancer Institute 20
Testing effectiveness (Phase 2)Study completedNCT00695409
What this trial is testing

Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma
City of Hope Medical Center 122
Testing effectiveness (Phase 2)Study completedNCT00048737
What this trial is testing

Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

Who this might be right for
LymphomaLeukemia
M.D. Anderson Cancer Center 70
Not applicableEnded earlyNCT01083563
What this trial is testing

Draining PLN and Synovial Inflammation in RA Knee Joints Pre and Post Anti-TNF or B Cell Depletion Therapy

Who this might be right for
Rheumatoid Arthritis
University of Rochester 7
Testing effectiveness (Phase 2)Study completedNCT00498043
What this trial is testing

Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma

Who this might be right for
Lymphoma, B-CellLymphoma, Large-Cell, Diffuse
Hospices Civils de Lyon 222
Testing effectiveness (Phase 2)Study completedNCT01086540
What this trial is testing

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Who this might be right for
Systemic Sclerosis-Associated PAH
National Institute of Allergy and Infectious Diseases (NIAID) 57
Large-scale testing (Phase 3)Study completedNCT00003280
What this trial is testing

Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma

Who this might be right for
Lymphoma
Swiss Cancer Institute 240
Early research (Phase 1)Study completedNCT04152148
What this trial is testing

A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients

Who this might be right for
Non-Hodgkin's Lymphoma
Bio-Thera Solutions 16
Testing effectiveness (Phase 2)Ended earlyNCT03125577
What this trial is testing

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

Who this might be right for
B-cell Malignancies
Shenzhen Geno-Immune Medical Institute 100
Early research (Phase 1)Looking for participantsNCT06313957
What this trial is testing

LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed B-cell Non-Hodgkin LymphomaRefractory B-cell Non-Hodgkin Lymphoma
Peking University Cancer Hospital & Institute 42
Large-scale testing (Phase 3)Study completedNCT02213263
What this trial is testing

PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

Who this might be right for
Follicular Lymphoma
Pfizer 394
Next Page